aflibercept vs bimatoprost
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aflibercept and bimatoprost. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Eylea
Lumigan
AHZANTIVE is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
Bimatoprost eye drops help lower pressure in the eye. It is used for people with open-angle glaucoma or ocular hypertension.
AHZANTIVE treats wet age-related macular degeneration (AMD). It also treats swelling in the macula (the central part of the retina) caused by retinal vein occlusion (RVO) or diabetic macular edema (DME). Additionally, it can treat diabetic retinopathy (DR), an eye disease caused by diabetes.
This medicine treats high pressure inside your eye. It is for people who have open-angle glaucoma or ocular hypertension. These conditions can damage the optic nerve and cause vision loss. Bimatoprost helps to lower the pressure and protect your vision.
AHZANTIVE is a VEGF inhibitor. VEGF is a protein that promotes the growth of new blood vessels. By blocking VEGF, AHZANTIVE helps to reduce the growth of abnormal blood vessels in the eye and decrease leakage.
Bimatoprost is like a natural substance in your body. It works by helping fluid drain better from inside your eye. This lowers the pressure in your eye.
- • Bleeding in the eye
- • Eye pain
- • Clouding of the lens of the eye (cataract)
- • Separation of the vitreous gel from the retina
- • Spots in your vision
- • Redness of the eye (conjunctival hyperemia)
- • Increased eyelash growth
- • Eye itching (ocular pruritus)
- Death 7,853
- Visual Impairment 2,013
- Blindness 1,459
- Endophthalmitis 1,372
- Visual Acuity Reduced 1,244
- Treatment Failure 3,077
- Ocular Hyperaemia 2,333
- Eye Irritation 1,841
- Madarosis 1,386
- Eye Pruritus 1,320
Injections with AHZANTIVE may cause serious eye infections (endophthalmitis), separation of the retina (retinal detachment), and inflammation of blood vessels in the retina. Tell your doctor right away if you have any signs of these problems. AHZANTIVE may also increase the risk of blood clots that can cause stroke or heart attack.
Bimatoprost can cause increased brown pigmentation of the iris, which is likely to be permanent. It can also cause your eyelashes to get longer, thicker, and more numerous. These eyelash changes are usually reversible when you stop using the medicine. This medicine may also cause inflammation inside the eye. Use caution if you have active inflammation in the eye. Macular edema has been reported with bimatoprost. Use with caution if you have risk factors for macular edema.
It is not known if AHZANTIVE can harm an unborn baby. AHZANTIVE should be used during pregnancy only if the benefit justifies the risk. It is also not known if AHZANTIVE passes into breast milk.
It is not known if bimatoprost is safe to use during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if bimatoprost passes into breast milk. Talk to your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare aflibercept with
Compare bimatoprost with
How to Read This aflibercept vs bimatoprost Comparison
aflibercept is classified in the Anti-VEGF (Ophthalmic Injection) drug class, while bimatoprost sits within the Prostaglandin Analog (Ophthalmic) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aflibercept has 13,941 submissions while bimatoprost has 9,957. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aflibercept or bimatoprost.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.